Burzynski Research Institute (BZYR) Change in Account Payables (2010 - 2025)
Burzynski Research Institute (BZYR) posted Change in Account Payables of $21158.0 for Q4 2025, up 1316.68% sequentially from -$1739.0 in Q3 2025, and up 135.55% YoY from $8982.5 in Q4 2024.
Burzynski Research Institute (BZYR) Change in Account Payables (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Change in Account Payables for 16 years, with the latest figure at $21158.0 in Q4 2025.
- Quarterly Change in Account Payables rose 135.55% year-over-year to $21158.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $27320.0 (up 1331.19% YoY) and the FY2025 annual result came in at $8007.0, up 324.92% from the prior year.
- Change in Account Payables grew to $21158.0 in Q4 2025 per BZYR's latest filing, from -$1739.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $61595.0 in Q2 2024 and troughed at -$59522.0 in Q4 2024.
- A 5-year average of $1174.8 and a median of -$1076.5 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables surged 772.38% in 2022, then sank 397.61% in 2024.
- Over 5 years, Change in Account Payables stood at -$17871.0 in 2021, then jumped by 182.34% to $14715.0 in 2022, then surged by 35.92% to $20000.0 in 2023, then tumbled by 397.61% to -$59522.0 in 2024, then soared by 135.55% to $21158.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered $21158.0, -$1739.0, and $8665.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 21,158.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 21,158.00 |
| Nov 30, 2025 | 21,158.00 |
| Aug 31, 2025 | -1,739.00 |
| Aug 31, 2025 | -1,739.00 |
| May 31, 2025 | 8,665.00 |
| May 31, 2025 | 8,665.00 |
| Feb 28, 2025 | -764.00 |
| Feb 28, 2025 | -764.00 |
| Nov 30, 2024 | -59,522.00 |
| Nov 30, 2024 | -59,522.00 |
| Aug 31, 2024 | 6,698.00 |
| Aug 31, 2024 | 6,698.00 |
| May 31, 2024 | 61,595.00 |
| May 31, 2024 | 61,595.00 |
| Feb 29, 2024 | -10,990.00 |
| Feb 29, 2024 | -10,990.00 |
| Nov 30, 2023 | 20,000.00 |
| Nov 30, 2023 | 20,000.00 |
| Aug 31, 2023 | -22,757.00 |
| Aug 31, 2023 | -22,757.00 |